The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization

International Ophthalmology

Volumn 33, Issue 5, 2013, Pages 507-513

  Acar, Banu Torun ^a   Halili, Elvin ^a   Acar, Suphi ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bevacizumab; Cornea; Neovascularization; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; OFLOXACIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HERPES SIMPLEX KERATITIS; HUMAN; KERATOPLASTY; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84890133219     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-013-9732-8     Document Type: Article

References (34)

1. Epstein RJ, Stulting RD, Hendricks RL, Harris DM (1987) Corneal neovascularization. Pathogenesis and inhibition. Cornea 64:250-257 (Pubitemid 18005952)
2. Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242-249 (Pubitemid 32751680)
3. Kabbnivar FI, Meropol NJ, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
5. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005) Maximum tolerated dose of a humanized anti-vaskular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048-1053 (Pubitemid 40797460)
6. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047 (Pubitemid 40797459)
7. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmology 113:363-372
8. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 89:1368-1370 (Pubitemid 41638883)
9. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Reen M, Lake JC, Chevez-Barrios P (2007) Inhibition of experimental corneal neovascularIsatIon by bevacizumab (Avastin). Br J Ophthalmol 91:804-807 (Pubitemid 46846656)
10. Kim TI, Kim SW, Kim S, Kim T, Kim EK (2008) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27:349-352 (Pubitemid 351440872)
11. Hashemian MN, Zare MA, Rahimi F, Mohammadpour M (2011) Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea 30:215-218
12. Vassileva PI, Hergeldzhieva TG (2009) Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 247:1701-1706
13. Liu Y, Cao J, Renard RA et al (2006) Low-dose, subconjunctival administration of VEGF trap inhibits suture-induced corneal neovascularization and inflammation. In: Proceeding of the association for research in vision and ophthalmology (ARVO) annual meeting, Fort Lauderdale, FL, 30 April-4 May 2006. ARVO, Rockville
14. Breier G, Albrecht U, Sterrer S, Risau W (1992) Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114:521-532
15. D'Amore PA (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35:3974-3979 (Pubitemid 24350660)
16. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT (2001) Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 75:9828-9835 (Pubitemid 32900118)
17. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative corneal transplantation studies research group. Ophthalmology 101:1536-1547 (Pubitemid 24347052)
18. Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ, All Contributors (2008) Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 86:1720-1724
19. Ferrara N, Leung DW, Phillips HS (1991) Molecular characterization and distribution of vascular endothelial growth factor. In: Muller EE, MacLeod RB (eds) Neuroendocrine perspectives. Springer, New York p 127
20. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964-970 (Pubitemid 26271462)
21. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625-1632 (Pubitemid 26271414)
22. Amano S, Rohan R, Kuroki M, Tolentino M, Adams AP (1998) Requirement for vascular endothelial growth factor in wound and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18-22 (Pubitemid 28040457)
23. Gan L, Fagerholm P, Palmblad J (2004) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82:557-563 (Pubitemid 39386968)
24. Cursiefen C, Rummelt C, Kuchle M (2009) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta 1 in human corneas with neovascularization. Cornea 19:526-533
25. Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514-2522 (Pubitemid 30624378)
26. You IC, Kang IS, Lee SH, Yoon KC (2009) Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 87:653-658
27. Zaki AA, Farid SF (2010) Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 88:868-871
28. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt K, Szurman P; Tübingen Bevacizumab Study Group (2008) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 86:322-328 (Pubitemid 351785106)
29. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR (2009) Subkonjoktival injection of bevacizumab (avastin)on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50:1659-1665
30. Hosseini H, Nejabat M, Mehryar M, Yazdehi T, Sedaghat A, Noori F (2007) Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 35:745-748 (Pubitemid 350090533)
31. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA (2008) Inhibition of corneal neovascularization by subconunctival bevacizumab in an animal model. Am J Ophthalmol 145:424-431
32. Awadein A (2007) Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 33:1991-1993 (Pubitemid 47615364)
33. Erdurmus M, Totan Y (2007) Subconjuntival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577-1579 (Pubitemid 47423342)
34. Bahar I, Kaiserman I, Mc Allum P, Rootman D, Slomovic A (2008) Subkonjunctival bevacizumab injection for corneal neovascularization. Cornea 27:142-147 (Pubitemid 351158729)